Neuraminidaseremmers bij verhoogd risico op griepcomplicaties: afgewogen en breed gedragen advies

Jaap T van Dissel; Roel A Coutinho; Marianne A B van der Sande

Neuraminidaseremmers bij verhoogd risico op griepcomplicaties: afgewogen en breed gedragen advies

Translated title of the contribution: Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations

Jaap T van Dissel, Roel A Coutinho, Marianne A B van der Sande

Department of Public Health

Research output: Contribution to journal › A2: International peer reviewed article (not A1-type) › peer-review

Abstract

It has been suggested that it is unwise to employ neuraminidase inhibitors in order to diminish the risk of influenza-related complications in cases of infection with the new influenza A(H1N1). However, the major argument, i.e. that the beneficial effects shown in the published evidence may be due to age differences between treatment and placebo groups, can easily be refuted. The Netherlands' policy to limit treatment to those patient groups who are considered at high risk of influenza complications is a sound one. In addition, it is endorsed by recent guidelines of the WHO and CDC.

Translated title of the contribution	Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations
Original language	Dutch
Article number	B486
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	153
ISSN	0028-2162
Publication status	Published - 2009

Access to Document

https://www.ntvg.nl/artikelen/neuraminidaseremmers-bij-verhoogd-risico-op-griepcomplicaties-afgewogen-en-breed-gedragen

Cite this

@article{43ca1f9894c8454da83c1cfb1e295d61,

title = "Neuraminidaseremmers bij verhoogd risico op griepcomplicaties: afgewogen en breed gedragen advies",

abstract = "It has been suggested that it is unwise to employ neuraminidase inhibitors in order to diminish the risk of influenza-related complications in cases of infection with the new influenza A(H1N1). However, the major argument, i.e. that the beneficial effects shown in the published evidence may be due to age differences between treatment and placebo groups, can easily be refuted. The Netherlands' policy to limit treatment to those patient groups who are considered at high risk of influenza complications is a sound one. In addition, it is endorsed by recent guidelines of the WHO and CDC.",

keywords = "Age Factors, Antiviral Agents/adverse effects, Centers for Disease Control and Prevention, U.S., Enzyme Inhibitors/adverse effects, Humans, Influenza A Virus, H1N1 Subtype, Influenza, Human/complications, Neuraminidase/antagonists & inhibitors, Oseltamivir/adverse effects, Practice Guidelines as Topic, Risk Factors, United States, World Health Organization",

author = "{van Dissel}, {Jaap T} and Coutinho, {Roel A} and {van der Sande}, {Marianne A B}",

note = "NPP",

year = "2009",

language = "Nederlands",

volume = "153",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu Van Loghum",

}

TY - JOUR

T1 - Neuraminidaseremmers bij verhoogd risico op griepcomplicaties: afgewogen en breed gedragen advies

AU - van Dissel, Jaap T

AU - Coutinho, Roel A

AU - van der Sande, Marianne A B

N1 - NPP

PY - 2009

Y1 - 2009

N2 - It has been suggested that it is unwise to employ neuraminidase inhibitors in order to diminish the risk of influenza-related complications in cases of infection with the new influenza A(H1N1). However, the major argument, i.e. that the beneficial effects shown in the published evidence may be due to age differences between treatment and placebo groups, can easily be refuted. The Netherlands' policy to limit treatment to those patient groups who are considered at high risk of influenza complications is a sound one. In addition, it is endorsed by recent guidelines of the WHO and CDC.

AB - It has been suggested that it is unwise to employ neuraminidase inhibitors in order to diminish the risk of influenza-related complications in cases of infection with the new influenza A(H1N1). However, the major argument, i.e. that the beneficial effects shown in the published evidence may be due to age differences between treatment and placebo groups, can easily be refuted. The Netherlands' policy to limit treatment to those patient groups who are considered at high risk of influenza complications is a sound one. In addition, it is endorsed by recent guidelines of the WHO and CDC.

KW - Age Factors

KW - Antiviral Agents/adverse effects

KW - Centers for Disease Control and Prevention, U.S.

KW - Enzyme Inhibitors/adverse effects

KW - Humans

KW - Influenza A Virus, H1N1 Subtype

KW - Influenza, Human/complications

KW - Neuraminidase/antagonists & inhibitors

KW - Oseltamivir/adverse effects

KW - Practice Guidelines as Topic

KW - Risk Factors

KW - United States

KW - World Health Organization

M3 - A2: Artikel in een internationaal wetenschappelijk tijdschrift met peer review, dat niet inbegrepen is in A1

C2 - 20051160

SN - 0028-2162

VL - 153

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

M1 - B486

ER -

Neuraminidaseremmers bij verhoogd risico op griepcomplicaties: afgewogen en breed gedragen advies

Abstract

Access to Document

Fingerprint

Cite this